JP2012519668A - ロイシンジッパーおよび滅菌αモチーフを含有するキナーゼ（ＺＡＫ）によって媒介される障害を治療するためのピリミジルアミノベンズアミド誘導体の使用 - Google Patents

ロイシンジッパーおよび滅菌αモチーフを含有するキナーゼ（ＺＡＫ）によって媒介される障害を治療するためのピリミジルアミノベンズアミド誘導体の使用 Download PDF

Info

Publication number
JP2012519668A
JP2012519668A JP2011552459A JP2011552459A JP2012519668A JP 2012519668 A JP2012519668 A JP 2012519668A JP 2011552459 A JP2011552459 A JP 2011552459A JP 2011552459 A JP2011552459 A JP 2011552459A JP 2012519668 A JP2012519668 A JP 2012519668A
Authority
JP
Japan
Prior art keywords
lower alkyl
phenyl
substituted
amino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011552459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519668A5 (enExample
Inventor
ファブロ，ドリアーノ
ダブリュ． マンレイ，ポール
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2012519668A publication Critical patent/JP2012519668A/ja
Publication of JP2012519668A5 publication Critical patent/JP2012519668A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011552459A 2009-03-06 2010-03-05 ロイシンジッパーおよび滅菌αモチーフを含有するキナーゼ（ＺＡＫ）によって媒介される障害を治療するためのピリミジルアミノベンズアミド誘導体の使用 Pending JP2012519668A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09154507 2009-03-06
EP09154507.9 2009-03-06
EP09166437.5 2009-07-27
EP09166437 2009-07-27
PCT/EP2010/052797 WO2010100248A1 (en) 2009-03-06 2010-03-05 Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)

Publications (2)

Publication Number Publication Date
JP2012519668A true JP2012519668A (ja) 2012-08-30
JP2012519668A5 JP2012519668A5 (enExample) 2013-04-18

Family

ID=42115422

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011552459A Pending JP2012519668A (ja) 2009-03-06 2010-03-05 ロイシンジッパーおよび滅菌αモチーフを含有するキナーゼ（ＺＡＫ）によって媒介される障害を治療するためのピリミジルアミノベンズアミド誘導体の使用

Country Status (11)

Country Link
US (1) US20120015968A1 (enExample)
EP (1) EP2403492A1 (enExample)
JP (1) JP2012519668A (enExample)
KR (1) KR20110132439A (enExample)
CN (1) CN102341102A (enExample)
AU (1) AU2010220262B2 (enExample)
BR (1) BRPI1013366A2 (enExample)
CA (1) CA2753637A1 (enExample)
MX (1) MX2011009310A (enExample)
RU (1) RU2011140404A (enExample)
WO (1) WO2010100248A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6697311B2 (ja) * 2016-04-01 2020-05-20 ショーワグローブ株式会社 手袋
CN108117553B (zh) * 2016-11-30 2019-08-16 暨南大学 炔苯基苯磺酰胺类选择性zak抑制剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533827A (ja) * 2002-07-05 2005-11-10 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼの阻害剤
JP2006521394A (ja) * 2003-03-24 2006-09-21 シグナル ファーマシューティカルズ，エルエルシー Ｊｎｋを阻害することにより、炎症または代謝性症状を治療または予防する方法
JP2009504674A (ja) * 2005-08-11 2009-02-05 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2315043C2 (ru) 2002-06-28 2008-01-20 Ниппон Синяку Ко., Лтд. Амидное производное, фармацевтическая композиция и терапевтические средства на его основе
BRPI0507030A (pt) * 2004-01-22 2007-06-05 Novartis Ag combinação de compostos orgánicos
WO2005118833A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
WO2007051862A1 (en) * 2005-11-07 2007-05-10 Novartis Ag Combination of organic compounds
KR20120049397A (ko) * 2006-11-03 2012-05-16 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
CN101185627B (zh) * 2007-12-14 2011-04-20 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼罗替尼缓释植入剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533827A (ja) * 2002-07-05 2005-11-10 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼの阻害剤
JP2006521394A (ja) * 2003-03-24 2006-09-21 シグナル ファーマシューティカルズ，エルエルシー Ｊｎｋを阻害することにより、炎症または代謝性症状を治療または予防する方法
JP2009504674A (ja) * 2005-08-11 2009-02-05 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5012010955; ＴＡＩＲＡ　ＭＡＥＫＡＷＡ: 'ＴＨＥ　ＢＣＲ-ＡＢＬ　ＴＹＲＯＳＩＮＥ　ＫＩＮＡＳＥ　ＩＮＨＩＢＩＴＯＲ　ＩＭＡＴＩＮＩＢ　ＡＮＤ　ＰＲＯＭＩＳＩＮＧ　ＮＥＷ　ＡＧＥＮＴＳ　以下備考' ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＬＩＮＩＣＡＬ　ＯＮＣＯＬＯＧＹ Ｖ１２　Ｎ５, 20071022, Ｐ３２７-３４０, ＳＰＲＩＮＧＥＲ *
JPN6014013539; Ｂｌｏｏｄ Ｖｏｌ．１１０, 2007, ｐｐ．４０５５-４０６３ *
JPN6014013540; Ｇｙｎｅｃｏｌｏｇｉｃ　Ｏｎｃｏｌｏｇｙ Ｖｏｌ．１０８, 2008, ｐｐ．１８２-１９０ *

Also Published As

Publication number Publication date
WO2010100248A1 (en) 2010-09-10
AU2010220262B2 (en) 2014-01-09
CN102341102A (zh) 2012-02-01
CA2753637A1 (en) 2010-09-10
AU2010220262A1 (en) 2011-09-08
MX2011009310A (es) 2011-10-13
KR20110132439A (ko) 2011-12-07
EP2403492A1 (en) 2012-01-11
RU2011140404A (ru) 2013-04-20
US20120015968A1 (en) 2012-01-19
BRPI1013366A2 (pt) 2016-03-29

Similar Documents

Publication Publication Date Title
KR101853596B1 (ko) Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법
US8604045B2 (en) Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis
WO2010019540A1 (en) Treatment of pulmonary arterial hypertension
JP2011528015A (ja) 線維症を治療するためのピリミジルアミノベンズアミド誘導体の使用
EP1843771B1 (en) Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
JP2012519668A (ja) ロイシンジッパーおよび滅菌αモチーフを含有するキナーゼ（ＺＡＫ）によって媒介される障害を治療するためのピリミジルアミノベンズアミド誘導体の使用
KR101376875B1 (ko) 전신 비만세포증의 치료를 위한 피리미딜아미노벤즈아미드유도체의 용도
KR20080004564A (ko) 과호산구성 증후군을 위한 피리미딜아미노벤즈아미드유도체
EP2186514B1 (en) Treatment of Malignant Peripheral Nerve Sheath Tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140924